down arrow

Cyclacel Pharmaceuticals, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US23254L8019
USD
1.42
-0.04 (-2.74%)

Dec 24

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.421.46

52 Week

1.16213.60
Valuation
Technical
Day's Volume

CASH

3.7 k

Shareholding (Mar 2025)

FII

0.02%

Held by 5 FIIs

DII

99.95%

Held by 0 DIIs

Promoter

0.00%

How big is Cyclacel Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Cyclacel Pharmaceuticals, Inc. has a market capitalization of 7.80 million, with net sales of 0.01 million and a net profit of -8.35 million over the last four quarters. The company reported shareholder's funds of -2.17 million and total assets of 4.09 million as of Dec 24.

Market Cap: As of Jun 18, Cyclacel Pharmaceuticals, Inc. has a market capitalization of 7.80 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Cyclacel Pharmaceuticals, Inc. reported net sales of 0.01 million and a net profit of -8.35 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of -2.17 million and total assets of 4.09 million.

Read More

What does Cyclacel Pharmaceuticals, Inc. do?

22-Jun-2025

Cyclacel Pharmaceuticals, Inc. develops anticancer drugs based on cell cycle biology and has a market cap of $7.80 million. The company reported no net profit recently and has a dividend yield of 24.30%.

Overview:<BR>Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology within the Pharmaceuticals & Biotechnology industry, focusing on the development of anticancer drugs.<BR><BR>Financial Snapshot:<BR>- Most recent Net Profit: 0 Million (Quarterly Results - Mar 2025)<BR>- Market-cap: USD 7.80 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 24.30%<BR>- Debt Equity: -1.13<BR>- Return on Equity: -272.53%<BR>- Price to Book: 2.55<BR><BR>Contact Details:<BR>- Address: 200 Connell Dr Ste 1500, BERKELEY HEIGHTS NJ: 07922-2811<BR>- Tel: 1 908 5177330<BR>- Fax: 1 866 2713466<BR>- Website: http://www.cyclacel.com/

Read More

Who are in the management team of Cyclacel Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Cyclacel Pharmaceuticals, Inc. includes Dr. David U'Prichard (Independent Chairman), Spiro Rombotis (CEO), and several directors, including Dr. Christopher Henney (Independent Vice Chairman) and Paul McBarron (CFO). The team features a blend of executive leaders and independent directors for diverse governance.

As of March 2022, the management team of Cyclacel Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Dr. David U'Prichard: Independent Chairman of the Board<BR>- Mr. Spiro Rombotis: President, Chief Executive Officer, Director<BR>- Dr. Christopher Henney: Independent Vice Chairman of the Board<BR>- Mr. Paul McBarron: Chief Financial Officer, Chief Operating Officer, Executive Vice President - Finance, Secretary, Director<BR>- Mr. Brian Schwartz: Director<BR>- Ms. Karin Walker: Director<BR>- Dr. Samuel Barker: Independent Director<BR>- Mr. Gregory Hradsky: Independent Director<BR>- Mr. Lloyd Sems: Independent Director<BR><BR>This team comprises a mix of executive leadership and independent directors, reflecting a diverse governance structure.

Read More

Is Cyclacel Pharmaceuticals, Inc. overvalued or undervalued?

25-Jun-2025

As of November 14, 2016, Cyclacel Pharmaceuticals is considered overvalued due to poor financial metrics, including a price-to-book ratio of 2.69 and an ROE of -272.53%, alongside significant underperformance against the S&P 500 with a year-to-date return of -94.56%.

As of 14 November 2016, Cyclacel Pharmaceuticals, Inc. has moved from a grade of risky to does not qualify, indicating a significant deterioration in its valuation outlook. The company is currently considered overvalued given its financial metrics and performance. Key ratios include a price-to-book value of 2.69, an EV to EBITDA of -0.36, and a return on equity (ROE) of -272.53%, which highlight the company's struggles in generating returns and profitability.<BR><BR>In comparison to its peers, Cyclacel's valuation metrics are concerning. For instance, SeqLL, Inc. has a valuation grade of risky with an EV to EBITDA of -8.8835, while Hoth Therapeutics, Inc. also does not qualify with an EV to EBITDA of -0.6107. These comparisons further reinforce the notion that Cyclacel is not positioned favorably within its industry. Additionally, the company's stock has significantly underperformed against the S&P 500, with a year-to-date return of -94.56%, suggesting a lack of investor confidence and further supporting the conclusion that Cyclacel Pharmaceuticals is overvalued.

Read More

Is Cyclacel Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of July 1, 2025, Cyclacel Pharmaceuticals has a mildly bearish trend, with mixed technical indicators showing underperformance at -95.00% year-to-date compared to the S&P 500's 12.22%.

As of 1 July 2025, the technical trend for Cyclacel Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD shows a mildly bullish signal on both weekly and monthly time frames, while the RSI indicates a bullish monthly signal but no signal on the weekly. However, the Bollinger Bands and moving averages are bearish on the daily time frame, contributing to the overall bearish sentiment. Dow Theory presents a mildly bearish stance on the weekly and mildly bullish on the monthly. <BR><BR>In terms of performance, the stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -95.00% versus the S&P 500's 12.22%, and a one-year return of -98.20% compared to 17.14% for the index.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 16 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

12.01%

stock-summary
Debt Equity

-1.18

stock-summary
Return on Equity

-176.43%

stock-summary
Price to Book

4.35

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-1 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-70.66%
0%
-70.66%
6 Months
-72.95%
0%
-72.95%
1 Year
-98.14%
0%
-98.14%
2 Years
-99.78%
0%
-99.78%
3 Years
-99.95%
0%
-99.95%
4 Years
-99.99%
0%
-99.99%
5 Years
-100.0%
0%
-100.0%

Cyclacel Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0.20%
EBIT Growth (5y)
-0.65%
EBIT to Interest (avg)
-18.70
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.13
Sales to Capital Employed (avg)
0.04
Tax Ratio
31.89%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.84%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.69
EV to EBIT
-0.36
EV to EBITDA
-0.36
EV to Capital Employed
-4.79
EV to Sales
4.79
PEG Ratio
NA
Dividend Yield
23.01%
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-272.53%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 4 Schemes (0.04%)

Foreign Institutions

Held by 5 Foreign Institutions (0.02%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -1,200.00% vs 96.67% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.30",
          "val2": "-5.00",
          "chgp": "74.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.30",
          "val2": "-0.10",
          "chgp": "-1,200.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs 0.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 50.44% vs -6.60% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.40",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-15.70",
          "val2": "-30.30",
          "chgp": "48.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.20",
          "val2": "-22.60",
          "chgp": "50.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-365,558.10%",
          "val2": "-72,140.50%",
          "chgp": "-29,341.76%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-1.30
-5.00
74.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-1.30
-0.10
-1,200.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -1,200.00% vs 96.67% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.40
-100.00%
Operating Profit (PBDIT) excl Other Income
-15.70
-30.30
48.18%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-11.20
-22.60
50.44%
Operating Profit Margin (Excl OI)
-365,558.10%
-72,140.50%
-29,341.76%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 50.44% vs -6.60% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Cyclacel Pharmaceuticals, Inc. stock-summary
stock-summary
Cyclacel Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors.
Company Coordinates stock-summary
Company Details
200 Connell Dr Ste 1500 , BERKELEY HEIGHTS NJ : 07922-2811
stock-summary
Tel: 1 908 5177330
stock-summary
http://www.cyclacel.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."